Cardiff Oncology Inc
CRDF2.565USD
-0.075-2.84%
Market hours （ET）Quotes delayed by 15 min
170.64MMarket Cap
LossP/E TTM
More Details of Cardiff Oncology Inc Company
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Company Info
Ticker SymbolCRDF
Company nameCardiff Oncology Inc
IPO dateJul 27, 2004
CEODr. Mark Erlander, Ph.D.
Number of employees32
Security typeOrdinary Share
Fiscal year-endJul 27
Address11055 Flintkote Ave
CitySAN DIEGO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92121
Phone18589527570
Websitehttps://cardiffoncology.com/
Ticker SymbolCRDF
IPO dateJul 27, 2004
CEODr. Mark Erlander, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Gary William Pace, Ph.D.
Dr. Gary William Pace, Ph.D.
Independent Director
Independent Director
1.33M
+26.05%
Ms. Lale White
Ms. Lale White
Independent Director
Independent Director
113.79K
--
Mr. James E. (Jamie) Levine
Mr. James E. (Jamie) Levine
Chief Financial Officer
Chief Financial Officer
67.72K
+12.86%
Dr. Rodney S. Markin, M.D., Ph.D.
Dr. Rodney S. Markin, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
31.06K
--
Dr. James O. Armitage, M.D.
Dr. James O. Armitage, M.D.
Independent Director
Independent Director
27.49K
--
Dr. Mark Erlander, Ph.D.
Dr. Mark Erlander, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
24.48K
--
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
20.00K
--
Dr. Tod Smeal, Ph.D.
Dr. Tod Smeal, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Mani Mohindru, Ph.D.
Dr. Mani Mohindru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Roger Sidhu, M.D.
Dr. Roger Sidhu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Gary William Pace, Ph.D.
Dr. Gary William Pace, Ph.D.
Independent Director
Independent Director
1.33M
+26.05%
Ms. Lale White
Ms. Lale White
Independent Director
Independent Director
113.79K
--
Mr. James E. (Jamie) Levine
Mr. James E. (Jamie) Levine
Chief Financial Officer
Chief Financial Officer
67.72K
+12.86%
Dr. Rodney S. Markin, M.D., Ph.D.
Dr. Rodney S. Markin, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
31.06K
--
Dr. James O. Armitage, M.D.
Dr. James O. Armitage, M.D.
Independent Director
Independent Director
27.49K
--
Dr. Mark Erlander, Ph.D.
Dr. Mark Erlander, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
24.48K
--
Revenue Breakdown
FY2025Q1
FY2024
FY2023
FY2022
No Data
By RegionUSD
Name
Revenue
Proportion
United States
109.00K
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Commodore Capital LP
8.09%
The Vanguard Group, Inc.
5.60%
BlackRock Institutional Trust Company, N.A.
5.32%
William Blair & Company, L.L.C. (Research)
3.79%
Pfizer Inc
3.63%
Other
73.56%
Shareholders
Shareholders
Proportion
Commodore Capital LP
8.09%
The Vanguard Group, Inc.
5.60%
BlackRock Institutional Trust Company, N.A.
5.32%
William Blair & Company, L.L.C. (Research)
3.79%
Pfizer Inc
3.63%
Other
73.56%
Shareholder Types
Shareholders
Proportion
Investment Advisor
17.41%
Hedge Fund
14.56%
Investment Advisor/Hedge Fund
8.49%
Research Firm
5.32%
Corporation
3.63%
Individual Investor
2.01%
Private Equity
0.86%
Bank and Trust
0.18%
Insurance Company
0.03%
Other
47.51%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
209
34.93M
52.51%
+1.36M
2025Q1
212
33.90M
51.14%
+3.13M
2024Q4
197
29.71M
44.66%
+10.83M
2024Q3
176
18.97M
39.69%
-1.89M
2024Q2
177
19.40M
43.04%
+3.79M
2024Q1
190
14.89M
33.18%
-2.33M
2023Q4
185
11.58M
25.77%
-8.71M
2023Q3
197
11.37M
25.45%
-9.63M
2023Q2
203
11.90M
26.66%
-13.64M
2023Q1
216
12.90M
29.30%
-10.68M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Commodore Capital LP
5.38M
8.09%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
3.12M
4.68%
+830.45K
+36.34%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.54M
5.32%
+907.00K
+34.45%
Mar 31, 2025
William Blair & Company, L.L.C. (Research)
1.75M
2.63%
+1.47M
+520.96%
Mar 31, 2025
Pfizer Inc
2.41M
3.63%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
1.45M
2.17%
+152.69K
+11.82%
Mar 31, 2025
Acorn Capital Advisors, LLC
1.44M
2.17%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.39M
2.1%
+411.55K
+41.87%
Mar 31, 2025
Pace (Gary William)
1.06M
1.59%
+7.80K
+0.74%
Apr 28, 2025
State Street Global Advisors (US)
940.28K
1.41%
+91.70K
+10.81%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Vanguard US Momentum Factor ETF
0.05%
iShares Micro-Cap ETF
0.04%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
iShares Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
View more
Vanguard US Momentum Factor ETF
Proportion0.05%
iShares Micro-Cap ETF
Proportion0.04%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
